Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

NCT04987203 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

343

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Tivozanib
DRUG: Nivolumab

Sponsor

AVEO Pharmaceuticals, Inc.

Collaborators

[object Object]
[object Object]